Shares of Vertex Pharmaceuticals Inc. VRTX slipped 2.37% to $477.52 Monday, on what proved to be an all-around dismal trading ...

ToolGen, Inc. (KOSDAQ 199800), led by CEO Jong Sang Ryu and recognized as a global leader in genome editing technology, announced today that it has filed a patent infringement lawsuit in the United ...

Learn more about whether SoundHound AI, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $51.3, a high estimate of $61.00, and a low estimate of $31.00. A 14.64% drop is evident in the current ...

Morgan Stanley lowered the firm’s price target on Vertex (VERX) to $55 from $60 and keeps an Overweight rating on the shares. The firm is ...

DA Davidson lowered the firm’s price target on Vertex (VERX) to $50 from $55 and keeps a Buy rating on the shares as part of a broader research note updating estimates within the firm’s coverage of ...

Learn more about whether Alkami Technology, Inc. or Vertex, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Las Vegas is playing host to Google Cloud Next 2025, an event unfolding at a critical moment for the technology industry. The ...

UiPath (NYSE: PATH), a leading enterprise automation and AI software company, today announced at Google Cloud Next 2025 the launch of its generative AI-based UiPath Medical Record Summarization agent, ...

Google is adding a new open source framework for building agents to its AI and machine learning platform Vertex AI, along ...

BOSTON, April 07, 2025--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2025 financial results on Monday, May 5, 2025 after the financial markets ...